XLO Q3 2025 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

XLOXilio Therapeutics, Inc.

$28M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+742.5% YoY

Gross Profit

$19M98.2% margin

Operating Income

-$2M-10.1% margin

Net Income

-$16M-85.4% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+135.8%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$134M

Total Liabilities

$142M

Stockholders' Equity

-$8M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$2M	+742.5%
Gross Profit	$19M	$2M	+727.5%
Operating Income	-$2M	-$15M	+86.9%
Net Income	-$16M	-$14M	-16.2%